Trilaciclib: clinical trials recruiting now
5
Recruiting trials
7
Conditions studied
3
US states with sites
3
Countries
FDA drug label
- FDA-approved
- Yes. Trilaciclib appears in the FDA drug-label database. Marketed as COSELA.
FDA-approved use
COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). COSELA is a kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. ( 1 )
Phase breakdown
Phase 2 3
Phase 3 1
Phase 4 1
Conditions being studied
Recruiting trials involving Trilaciclib
- Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
- Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
- Study of Trilaciclib and Lurbinectidin
- Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
- Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Common questions
Is Trilaciclib FDA-approved?
Yes, marketed as COSELA.
How many recruiting trials involve Trilaciclib?
5 recruiting trials across 7 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.